Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
about
Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.FRED (a Framework for Reconstructing Epidemic Dynamics): an open-source software system for modeling infectious diseases and control strategies using census-based populations.Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventionsImproving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.Vaccine allocation in a declining epidemic.Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine seasonSerological memory and long-term protection to novel H1N1 influenza virus after skin vaccinationThe benefits to all of ensuring equal and timely access to influenza vaccines in poor communitiesCost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.High TNF-α levels in resting B cells negatively correlate with their response.Aging, cytomegalovirus (CMV) and influenza vaccine responses.Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
P2860
Q30203021-819BE2FF-18CE-4FB1-946E-A2361B0FEEE3Q30354231-3ECC4945-2944-4508-B627-3A0355EF1DE1Q30402629-FBAD702C-7A7D-4178-BE8F-AC74B8DFC5D7Q30403117-D5650A4C-4500-4A87-92AF-A19D7A0545AEQ30418929-64F50636-44B3-4409-BF0A-1C89D9B83E5EQ30429661-97E7254D-3470-42BD-8192-DF537C9EBC33Q35129385-8A1346D3-A27C-4796-A218-D1DDEF0A8B0AQ36066015-7E5DA146-BBDD-4F72-8306-B926F143FDF1Q36827449-80D83942-1A68-4A79-9BBA-B3B966E8223EQ37150722-FCC2DD71-F6EC-47C8-B6A9-4541D59C3E69Q37584878-56B11DB6-BA45-4385-8A21-9FBBDD29C551Q37707181-B7E931FC-D65B-427D-AFFD-4B3BF217B4AFQ38640148-554F204C-48D7-4AF2-8AAF-2835382A4BE1Q38729177-A182A0C2-41DF-4B03-A944-33680EEF3B59Q38840723-6E3DA801-2311-4075-BA14-A684B0364339Q39310460-558EFD38-CB79-4013-8083-4DF44EFDA30AQ48164516-BEF21F77-31F9-4FE1-94FD-668E8D059EE2
P2860
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@ast
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@en
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@nl
type
label
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@ast
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@en
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@nl
prefLabel
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@ast
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@en
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@nl
P2093
P2860
P1433
P1476
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income
@en
P2093
Diane K Wagener
Diane S Lauderdale
Sylvia M Tan
P2860
P304
P356
10.1016/J.VACCINE.2010.07.037
P407
P577
2010-07-30T00:00:00Z